DarioHealth (DRIO) Peer Comparison

$7.18

$0.20 (2.87%)

As on 04-Sep-2026 16:00EDT

Market cap

$71 Mln

Revenue (TTM)

$21 Mln

P/E Ratio

--

P/B Ratio

1.2

Div. Yield

0 %

Edit

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	71	12,650	10,638	9,762	9,459
Revenue ($ Mln)	21	1,505	613	2,589	785
Net Profit ($ Mln)	67.78	160.59	-188.05	222.40	41.54
Net Margin (%)	322.77	10.67	-30.68	8.59	5.29
RoE (%)	110.20	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	232.78
Price-To-Book	1.24	8.31	15.27	1.36	4.62

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	21.00	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	9.22	483.98	127.96	1,245.50	384.30
Gross Profit	12.67	942.44	393.22	1,343.60	347.62
Operating Expenses	80.83	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-69.05	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	68.14	203.83	-192.83	350.40	52.15
Provision for Tax	0.36	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	67.78	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	55.09	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	31.92	210.18	135.71	2,116.80	705.49
Current Liabilities	9.58	233.78	102.33	961.30	132.66
Total Liabilities	110.08	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	74.46	630.60	404.74	7,231.50	1,749.63
Current Assets	22.13	1,344.12	515.78	3,020.50	1,200.55
Total Assets	110.08	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	32.41	212.71	102.84	1,203.70	690.94
Net Current Assets	12.55	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-25.94	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-4.34	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	24.31	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-41.33	11.76	-22.53	8.98	1.79
ROE (%)	110.20	10.86	-28.10	3.04	1.97
ROA (%)	60.45	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-150.30	13.63	-30.58	-5.99	9.87
Net Margin (%)	322.77	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	-22.65	17.55	41.55	1.37	16.49
EBIT Growth (%)	24.09	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	253.42	8.72	-102.66	-30.32	400.42
EPS Growth (%)	167.05	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	357.31	17.33	-12.65	2.19	2.16

Valuation Ratios

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-13.54	68.93	-34.59	--	189.42
Price / Book Value	1.24	8.31	15.27	--	4.62
Dividend Yield (%)	0.00	0.00	0.00	--	0.00
EV/EBITDA	-2.43	55.45	-73.80	--	77.00
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.56	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.01	0.01	0.00	0.06	0.01
Current Ratio	2.31	5.75	5.04	3.14	9.05
Quick Ratio	1.92	3.86	4.46	2.33	7.64
Interest Coverage	13.19	157.91	-38.31	8.18	1.92

Operating Efficiency Ratios

	DarioHealth (DRIO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	7.38	12.65	22.67	17.06	20.09
Asset Turnover	0.19	0.74	0.59	0.24	0.26
Receivable days	65.53	46.54	60.95	65.39	72.41
Inventory Days	170.85	331.92	193.84	221.09	146.53
Payable days	112.53	26.16	60.19	37.02	29.05
Cash Conversion Cycle	123.86	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly